NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









eGenesis

eGenesis

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://egenesisbio.com/

Last Round

Series D

Sep 4, 2024

Total Funding Raised

$454M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

eGenesis is a biotechnology company that specializes in gene editing and genome engineering to revolutionize solid organ and therapeutic cell transplantation for life-threatening diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

xenotransplantationpig-to-human transplantgene editingporcine organorgan shortageCRISPRgenetically engineered organbiotechend-stage organ failuregenomic engineeringtransplant medicineclinical-stage biotechorgan support system

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

eGenesis Comparables

Compare eGenesis with similar companies based on industry and business-model similarity.

eGenesis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
United Therapeutics
81%
Makana Therapeutics
79%
NZeno
79%

eGenesis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 4, 2024
Series CMar 2, 2021
Series BNov 7, 2019
Series AMar 16, 2017

Key People

Founding team and executive leadership

Michael Curtis

President And CEO

Executive Team

Knut Niss

Chief Technology Officer

Executive Team

Glenn S. Vraniak

Chief Financial Officer

Executive Team

eGenesis Investors

Notable investors and investment history

eGenesis investors
InvestorRounds
SymBiosis Capital ManagementSeries C
Farallon Capital ManagementSeries D, Series C
LifeSci Venture PartnersSeries C
Khosla VenturesSeries D, Series B, Series A, Series C
ParkwoodSeries D
ARCH Venture PartnersSeries D, Series B, Series C, Series A
Eisai InnovationSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Conducting clinical study for EGEN-2784 at Massachusetts General Hospital.

  • Mar 24, 2026

    Named to Fast Company's World's Most Innovative Companies list for 2026.

eGenesis Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

eGenesis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about eGenesis's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range153
Year Founded2015
Last FundingSep 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.